Myth of IP Theft: How India’s Evolving Patent Regime is Powering Pharma Innovation

“Show me one instance where we have illegally copied any trademarks, patents, or copyrighted technology,” asserted Union Commerce and Industry Minister Piyush Goyal in a recent press interaction in Bern, responding to unfounded claims of intellectual property theft by Indian pharmaceutical companies.

This strong rebuttal isn’t just a defence—it’s a reflection of the remarkable transformation of India’s pharmaceutical industry, especially from the lens of intellectual property rights. Over the past two decades, Indian pharma has shed its image as a mere generics player to emerge as a global hub of drug discovery, innovation, and IP-driven growth. The numbers—and patents—tell a compelling story.

From Process to Product: A Patent Regime That Changed Everything

The turning point came in 2005, when India amended its patent law to allow product patents—a move aligned with the TRIPS agreement under WTO. This shift empowered domestic companies to invest in R&D, protect their inventions, and compete globally not just on cost, but on innovation.

Back in 2005, only 3 pharmaceutical patents were filed. Fast forward to today, India has consistently filed over 1,000 pharmaceutical patents annually. According to the World Intellectual Property Indicators (WIPI) 2024, India recorded a 15.7% growth in overall patent applications in 2023—its fifth consecutive year of double-digit growth—placing it among the top 6 global patent filers.

This rise isn’t accidental. It’s the result of a maturing innovation ecosystem, strengthened IP frameworks, and regulatory reforms that encourage faster approvals and robust clinical trial systems.

From Generics Giant to Global R&D Player

The shift from a generics-only model to one that balances access, affordability, and innovation has enabled Indian firms to climb up the value chain. Indian Companies are not just producing drugs—they’re conducting clinical trials for new chemical entities and novel therapies.

This transformation is also reflected in the market size: from $8 billion in 2005–06, India’s pharmaceutical industry has grown to over $50 billion in 2023–24, with $ 26.5 billion in exports alone. Every third tablet consumed in the U.S. is manufactured in India, a testament to the global confidence in Indian pharma IP and quality.

How Patents Drive Investor Confidence and Innovation

For startups and scale-ups in the pharma space, patents are more than legal shields—they're innovation assets. They provide:

• Monetization opportunities through licensing

• Attractive IP portfolios for VC/investor funding

• Competitive barriers against copycats

• Entry points into global markets with patent compliance

At Einfolge Technologies, we’ve seen a surge in patentability search, drafting, and filing services from Indian pharmaceutical startups seeking to align with global IP standards. Our team empowers clients to build defensible, high-quality patents that support both regulatory and commercial strategies.

TRIPS, Flexibilities & the Balance with Public Health

While embracing innovation, India has also upheld public health priorities. Provisions like Section 3(d) of the Indian Patent Act prevent evergreening of patents and ensure affordable access to essential medicines. Far from being a loophole, it's a global model for IP-balanced healthcare. Even during the COVID-19 pandemic, India’s call for a TRIPS waiver was backed by over 100 nations—highlighting its leadership in health equity.

Yet, there are emerging concerns over TRIPS-plus provisions being pushed through Free Trade Agreements (FTAs), which could threaten India’s current IP-flexible regime. At Einfolge, we advocate for smart IP strategies that align with both global obligations and national interests.

The Road Ahead: A Pharma Patent Powerhouse in the Making

The Indian pharmaceutical industry’s journey is a lesson in how IP reform, global alignment, and national innovation policy can drive both industry growth and societal impact. With robust patent laws, progressive regulatory frameworks, and world-class manufacturing infrastructure, India is set to not just remain the pharmacy of the world but become a leader in pharmaceutical innovation.

Ready to Protect Your Innovation?

At Einfolge Technologies, we help pharma innovators safeguard their R&D outcomes through comprehensive IP solutions—from patent landscape analysis to global filings. Let’s turn your ideas into protected assets that attract funding, partnerships, and global opportunities.

📩 Get in touch: info@einfolge.com

🌐 Visit us: www.einfolge.com